echo "";

Press center

08 June 2020

During 2019, subsidiaries of the Russian Venture Company (RVC), managed by the RVC Infrafund, left 28 venture projects. Total revenues from exits and remaining in the portfolio of companies exceeded 430 million rubles. Promised assets in fund portfolios rose by more than 90% over the year.

24 March 2020

Portfolio Company of Biofund RVC National BioService (NBS) will provide an opportunity for accelerated testing of anti-coronavirus medicines and test systems that Russian developers are working on today. Reducing the duration of preclinical studies and technical testing will be possible through the use of tissue microchips.

03 June 2019

Roszdravnadzor has included the Center of Genetics and Reproductive Medicine "Genetico", part of the RVC Biofund's portfolio, in the list of medical entities engaged in clinical trials of medical devices for in vitro diagnostics.

15 November 2018

On November 15, the Biofund's portfolio company of the RVC National BioService opened the NBS-YUG biobank on the basis of the Research Institute of Medical Primatology of the Ministry of Science and Higher Education of Russia.

1 2 3 4 5  |